iBio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IBIO Nasdaq 2836 ibioinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for iBio, Inc.

iBio Announces $26 Million Private Placement - Jan 9th, 2026 5:00 am
iBio Insiders Placed Bullish Bets Worth US$655.0k - Dec 20th, 2025 5:07 am
BC-Most Active Stocks - Dec 10th, 2025 8:30 am
iBio to Participate in the 8th Annual Evercore Healthcare Conference - Nov 24th, 2025 2:15 pm
iBio, Inc. (IBIO) Reports Q1 Loss - Nov 12th, 2025 3:15 pm
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update - Nov 12th, 2025 2:01 pm
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance - Oct 30th, 2025 5:00 am
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Oct 23rd, 2025 5:00 am
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 - Oct 21st, 2025 5:00 am
iBio Full Year 2025 Earnings: US$1.75 loss per share (vs US$4.03 loss in FY 2024) - Sep 6th, 2025 7:28 am
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - Sep 5th, 2025 5:30 am
iBio Announces Closing of $50 Million Public Offering - Aug 25th, 2025 5:00 am
iBio Announces Pricing of $50 Million Public Offering - Aug 19th, 2025 6:01 am
iBio Announces Proposed Public Offering - Aug 18th, 2025 2:01 pm
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - Jun 24th, 2025 5:00 am
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - Jun 23rd, 2025 2:15 pm
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - Jun 16th, 2025 5:00 am
Insider Buyers At iBio Likely Disappointed With 23% Slide - May 11th, 2025 7:25 am
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - May 5th, 2025 6:00 am
iBio Reports Fiscal Third Quarter 2025 Financial Results - May 2nd, 2025 6:00 am